Compare GameStop Corp. (GME) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs GeneDx Holdings Corp — how do they compare? GameStop Corp. trades at $26.4 (market cap $12.75B), while GeneDx Holdings Corp trades at $67.94 (market cap $2.02B). The key difference: GameStop Corp. is far larger — about 6.3× GeneDx Holdings Corp's market cap, and GameStop Corp. is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and GeneDx Holdings Corp for 19 Days on average.
| GME | WGS | |
|---|---|---|
Market Cap | $12.75B | $2.02B |
Volume | 13,026,993 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $167.51 |
52-Week Low | $17.87 | $34.51 |
Typical Hold Time | 62 Days | 19 Days |
Enterprise Value | $12.03B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GameStop (GME) trades at $26.37, up 7.28% in 24 hours, with a bullish technical signal and strong insider buying by CEO Ryan Cohen. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, though revenue declined to $3.82 billion. Valuation ratios include a P/E of 16.63 and P/S of 4.22, while analyst consensus remains mixed with 16.67% buy ratings.
The outlook hinges on sustained profitability and strategic shifts, but risks include revenue volatility and competitive pressures. Insider confidence provides near-term support, yet the stock faces headwinds from cautious Wall Street sentiment and execution challenges in a declining physical retail environment.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
